Head to Head Survey: Evaxion A/S (NASDAQ:EVAX) vs. American Well (NYSE:AMWL)

American Well (NYSE:AMWL) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares American Well and Evaxion A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Well	$249.32 million	0.73	-$95.70 million	($5.42)	-2.02
Evaxion A/S	$7.53 million	3.46	-$7.71 million	($1.47)	-2.12

Evaxion A/S has lower revenue, but higher earnings than American Well. Evaxion A/S is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.0% of American Well shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 12.8% of American Well shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares American Well and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Well	-37.02%	-32.11%	-24.12%
Evaxion A/S	N/A	-73.56%	-37.45%

Risk and Volatility

American Well has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for American Well and Evaxion A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Well	1	3	1	0	2.00
Evaxion A/S	1	0	5	0	2.67

American Well currently has a consensus price target of $7.20, indicating a potential downside of 34.13%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 252.56%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than American Well.

Summary

Evaxion A/S beats American Well on 8 of the 14 factors compared between the two stocks.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.